EU regulators expand Praluent’s label
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Read More
Tag: Praluent
Sanofi, Regeneron to cut price of Praluent
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
Read More
Sanofi/Regeneron unveil more positive data for PCSK9 inhibitor
Sanofi and Regeneron have unveiled new data further backing the safety and efficacy of PCSK9 inhibitor Praluent in lowering cholesterol in patients with diabetes.
Read More
Praluent slashes need for apheresis treatment
Sanofi/Regeneron’s cholesterol buster Praluent reduced the need for apheresis treatment in patients with very high cholesterol by 75 percent versus a placebo, show findings from the Phase III ODYSSEY ESCAPE trial.
Read More
Six new drugs win funding nod for NHS Scotland
Treatment cost regulators for the NHS in Scotland have approved routine funding for six medicines, offering patients new treatment options for blood cancer, skin cancer, high cholesterol, diabetes, psoriatic arthritis, and infections in people with cystic fibrosis.
Read More
Five new medicines make it onto the NHS
NICE has published new guidelines endorsing NHS use of five medicines, widening treatment options for some patients with lung cancer, high cholesterol, melanoma and the skin condition hidradentitis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
